PAOG Takes CBD Pharmaceutical Research Global To T
Post# of 103076
(Total Views: 84)
Posted On: 09/15/2020 10:54:51 AM
PAOG Takes CBD Pharmaceutical Research Global To Target $5.8 Billion Market
Press Release | 09/15/2020
PAOG Takes CBD Pharmaceutical Research Global To Target $5.8 Billion Market
PR Newswire
SANDUSKY, Ohio, Sept. 15, 2020
SANDUSKY, Ohio, Sept. 15, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) Announces a multifold, international research initiative to advance its hemp derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD).
The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
This Friday, September 18, 2020, PAOG CEO James C. DiPrima will discuss in an interview with Donald Baillargeon of MoneyTV, PAOG's multifold international approach to engaging a Contract Research Organization (CRO) to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG's RespRx as a COPD treatment.
Grand View Research projects that the cannabis pharmaceutical market will reach a size of $5.8 billion by 2027.
On Friday, DiPrima will also discuss the recently published Goldman Small Cap Analyst Research Update on PAOG that includes target pricing.
Press Release | 09/15/2020
PAOG Takes CBD Pharmaceutical Research Global To Target $5.8 Billion Market
PR Newswire
SANDUSKY, Ohio, Sept. 15, 2020
SANDUSKY, Ohio, Sept. 15, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) Announces a multifold, international research initiative to advance its hemp derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD).
The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
This Friday, September 18, 2020, PAOG CEO James C. DiPrima will discuss in an interview with Donald Baillargeon of MoneyTV, PAOG's multifold international approach to engaging a Contract Research Organization (CRO) to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG's RespRx as a COPD treatment.
Grand View Research projects that the cannabis pharmaceutical market will reach a size of $5.8 billion by 2027.
On Friday, DiPrima will also discuss the recently published Goldman Small Cap Analyst Research Update on PAOG that includes target pricing.
(0)
(0)Scroll down for more posts ▼